5 recruiting, 3 completed, 1 unknown, 1 withdrawn. 3 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 3 | Completed 1, Recruiting 1, Withdrawn 1 |
Follow Qifu Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Steroids-Based Screening for Primary Aldosteronism Steroid-Based Screening (LC-MS/MS) - Primary Aldosteronism, Hypertension | Recruiting | Qifu Li | 406 | 2025-04-15 | 2026-04-28 | |
| Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion complete ACTH stimulation test the day after surgery and complete ACTH stimulation test 1 or 4 week for patients with Adrenal Insufficiency - Primary Aldosteronism, Autonomous Cortisol Secretion | Recruiting | Qifu Li | 521 | 2025-01-02 | 2026-05-01 | |
| Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion 68Ga-Pentixafor PET/CT - Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion | Recruiting | Qifu Li | 97 | 2024-08-12 | 2024-10-10 | |
| 68Ga-Pentixafor PET/CT Versus Adrenal Vein Sampling in Diagnosing Unilateral Subtype of Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion (PREDICT) 68Ga-Pentixafor PET/CT, AVS - Primary Aldosteronism, Autonomous Cortisol Secretion | Not applicable | Recruiting | Qifu Li | 178 | 2024-08-01 | 2026-02-05 |
| Pathological Type，Gene Mutation and Clinical Characteristics of Unilateral Primary Aldosteronism Tissue specimens were stained by histopathology of hematoxylin-eosin - Primary Aldosteronism | Unknown | Qifu Li | 100 | 2023-12-01 | 2024-09-19 | |
| 68Ga-Pentixafor PET/CT for the Subtyping Diagnosis of Primary Aldosteronism 68Ga-Pentixafor PET/CT imaging - Primary Aldosteronism | Completed | Qifu Li | 100 | 2021-11-11 | 2022-07-15 | |
| Environment, Inflammation and Metabolic Diseases Study observe - Endocrine Disease, Metabolic Disorders | Recruiting | Qifu Li | 8000 | 2020-12-25 | 2026-04-06 | |
| The Water Intake Trail and Primary Aldosteronism Postoperation(WIT-PAP) Hydration - Hyperaldosteronism, Renal Insufficiency | Not applicable | Withdrawn | Qifu Li | 2019-12-01 | 2020-07-15 | |
| Primary Aldosteronism In Hypertensive Patients in China Aldosterone/renin ratio (ARR) testing, Confirmatory tests - Hyperaldosteronism; Primary, Hypertension Secondary | Completed | Qifu Li | 3500 | 2017-06-03 | 2020-10-23 | |
| Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment glimepiride, glargine and metformin - Diabetes Mellitus, Type 2 | Not applicable | Completed | Qifu Li | 40 | 2014-01-01 | 2016-01-28 |
Hyperaldosteronism (8) · Hypertension (3) · Adrenal Insufficiency (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Endocrine System Diseases (1) · Hypoglycemia (1) · Metabolic Diseases (1) · Renal Insufficiency (1)
Insulin Glargine (1) · Metformin (1) · glimepiride (1)
China (10)
Jun Cai, phD (1) · Li Qifu (1) · Li Qifu, PhD (1)
PMID 32327102, PMID 26934393, PMID 15657580, PMID 29279316, PMID 35218017, PMID 35418526, PMID 21270113, PMID 22743644, PMID 25002246, PMID 28385310, PMID 28576687, PMID 30590677, PMID 33447758, PMID 33796078, PMID 36795418, PMID 36974473, PMID 17161262, PMID 19721021, PMID 20200334, PMID 21593113, PMID 23231595, PMID 23385627, PMID 25958045, PMID 26760044, PMID 27172433, PMID 27315757, PMID 27534428, PMID 27751767, PMID 27886747, PMID 29202495, PMID 29542002, PMID 29709927, PMID 29801012, PMID 29987110, PMID 30865224, PMID 31476901, PMID 32206838, PMID 32717746, PMID 32890265, PMID 34558612, PMID 35380982, PMID 35452014, PMID 35487459, PMID 35900323, PMID 36070424, PMID 37410097, PMID 38561283